Publications

Pond, G. R., A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, J. M. Burke, J. R. Caton, M. T. Fleming, and G. Sonpavde. “Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC).” J Clin Oncol 29, no. 7_suppl (March 2011): 185.

PMID
27968482
Scholars@Duke

Kelly, Ronan J., Arun Rajan, Jeremy Force, Ariel Lopez-Chavez, Corrine Keen, Liang Cao, Yunkai Yu, et al. “Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.” Clin Cancer Res 17, no. 5 (March 1, 2011): 1190–99. https://doi.org/10.1158/1078-0432.CCR-10-2331.

PMID
21224376
Full Text

Sinnathamby, G., J. Zerfass, J. Hafner, P. Block, Z. Nickens, A. Hobeika, A. A. Secord, H. K. Lyerly, M. A. Morse, and R. Philip. “ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.” Clin Exp Immunol 163, no. 3 (March 2011): 324–32. https://doi.org/10.1111/j.1365-2249.2010.04298.x.

PMID
21175594
Full Text

Armstrong, A. J., M. Haggman, W. M. Stadler, J. R. Gingrich, V. J. Assikis, O. Nordle, G. Forsberg, M. A. Carducci, and R. Pili. “Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups.” Journal of Clinical Oncology 29, no. 7_suppl (March 1, 2011): 126–126. https://doi.org/10.1200/jco.2011.29.7_suppl.126.

Full Text

Somarelli, J. A., A. Mesa, R. Rodriguez, R. Avellan, L. Martinez, Y. J. Zang, E. L. Greidinger, and R. J. Herrera. “Epitope mapping of the U1 small nuclear ribonucleoprotein particle in patients with systemic lupus erythematosus and mixed connective tissue disease.” Lupus 20, no. 3 (March 2011): 274–89. https://doi.org/10.1177/0961203310387180.

PMID
21362751
Full Text

Pond, G. R., A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, J. M. Burke, J. R. Caton, M. T. Fleming, and G. Sonpavde. “Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC).” Journal of Clinical Oncology 29, no. 7_suppl (March 1, 2011): 185–185. https://doi.org/10.1200/jco.2011.29.7_suppl.185.

Full Text

Sonpavde, G., G. R. Pond, W. R. Berry, R. De Wit, M. A. Eisenberger, I. Tannock, and A. J. Armstrong. “Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.” Journal of Clinical Oncology 29, no. 7_suppl (March 1, 2011): 118–118. https://doi.org/10.1200/jco.2011.29.7_suppl.118.

Full Text

Bauer, Christina M., Anna M. Ray, Bronwen A. Halstead-Nussloch, Robert G. Dekker, Victoria M. Raymond, Stephen B. Gruber, and Kathleen A. Cooney. “Hereditary prostate cancer as a feature of Lynch syndrome.” Fam Cancer 10, no. 1 (March 2011): 37–42. https://doi.org/10.1007/s10689-010-9388-8.

PMID
20872076
Full Text

Farenhorst, M, Hilhorst, A, Thomas, MB, and Knols, BGJ. "Development of fungal applications on netting substrates for malaria vector control." Journal of Medical Entomology 48, no. 2 (March 2011): 305-313.

PMID
21485366
Full Text

McKay, James D., Therese Truong, Valerie Gaborieau, Amelie Chabrier, Shu-Chun Chuang, Graham Byrnes, David Zaridze, et al. “A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium.” Plos Genet 7, no. 3 (March 2011): e1001333. https://doi.org/10.1371/journal.pgen.1001333.

PMID
21437268
Full Text

Pages